16 results about "Combination chemotherapy" patented technology

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The application discloses a kind of block copolymer and its preparation method and application, the application designs and synthesizes a kind of block copolymer mPEG-PLG-COOH-CD, utilize the host molecule β-CD with guest molecule IDO-1 inhibitor (such as Epa) and Pt class chemotherapy drug (such as cisplatin) with large cavity structure, by hydrophilic and hydrophobic interaction, host-guest recognition, coordination effect common assembly into supramolecular nanomedicine.Supramolecular nanomedicine simultaneously carries Pt class chemotherapy drug and IDO-1 inhibitor.Under the action of weak acid in tumor cell, nanomedicine swells, expose drug, and high concentration of Cl- will destroy the non-covalent bond force inside nanomedicine, quickly release chemotherapy drug and IDO-1 inhibitor, while activating chemotherapy and immunotherapy, realize the efficient combination of two kinds of therapy.In situ activation of chemotherapy not only directly kills cancer cells, but also activates the anti-tumor immunity of body.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating ovarian cancer, and the pharmaceutical composition is prepared from the following components in parts by weight: 5-20 parts of cortex phellodendri, 5-20 parts of rhizoma atractylodis, 5-20 parts of radix achyranthis bidentatae, 5-20 parts of oldenlandia diffusa, 5-20 parts of radix trichosanthis, 5-20 parts of cassia twig, 20-40 parts of radix astragali and 20-40 parts of semen coicis. The pharmaceutical composition provided by the invention is suitable for ovarian cancer postoperative combined chemotherapy, and can significantly reduce the incidence rate of adverse reactions of chemotherapy, improve the chemotherapy effect and compliance, and reduce the toxic and side effects of chemotherapy drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to a group of markers for predicting serious adverse reactions of wide-period small cell lung cancer immune combined chemotherapy and application thereof. The biomarker combination is easy and convenient to sample, and biopsy tissue does not need to be provided. The total T cell percentage is CD3 + / CD45 +, the T cell toxic cell percentage is CD3 + / CD8 + / CD45 +, and the combined combination of the two can predict the occurrence of treatment-related adverse reactions greater than or equal to level 3 of a wide-period small cell lung cancer patient treated by ICI combined chemotherapy, and the combined prediction efficiency is superior to that of a single index. In the training set, the area under the AUC curve of the combined prediction model is 0.852, the optimal Cut-off value is 0.39, the sensitivity is 87.5%, and the specificity is 83.3%. In the constructed prediction model by applying independent external verification, the AUC of the combined prediction model is 0.847, the sensitivity of the model is 85.2%, and the specificity is 73.9%. The method has practicability, and provides precise treatment guidance for clinical medicine.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention discloses saRNA for activating AMBRA1 transcription, modified saRNA and application of the saRNA and the modified saRNA. AMBRA1 is used as a target spot, saRNA sequences targeting an AMBRA1 promoter region are designed, 31 saRNA sequences and saRNA modified by the saRNA sequences are obtained through screening, and the saRNA sequences and the saRNA modified by the saRNA sequences can up-regulate the expression level of AMBRA1 in tumor cells so as to regulate the cell cycle and inhibit the proliferation, migration and invasion ability of the tumor cells. The invention further studies the feasibility of the saRNA combined chemotherapeutic drug as a tumor combined treatment scheme, and the combined administration of the saRNA and the chemotherapeutic drug further significantly inhibits the proliferation ability of tumor cells, increases apoptosis, and enhances the sensitivity of the tumor cells to the chemotherapeutic drug, so that the prognosis of tumor patients is expected to be improved; the saRNA or the modified saRNA provided by the invention has an application prospect in the aspects of preparation of anti-tumor drugs and preparation of anti-tumor drug combined therapy.

The application name is the application of METTL3 inhibitor combined with chemotherapy drugs to cervical cancer. It belongs to the field of antitumor drugs. Experiments prove that METTL3 inhibitor STM2457 can be used to treat cervical cancer; at the same time, it is proved that STM2457 can increase the sensitivity of the chemotherapeutic drug cisplatin for treating cervical cancer. Through experiments, the effect of using METTL3 inhibitor STM2457 alone on the growth of cervical cancer cells is understood; the effect of METTL3 inhibitor STM2457 combined with the chemotherapeutic drug cisplatin on the survival, proliferation and apoptosis-inducing ability of cervical cancer cells is understood; in vivo experiments on animals verify the effect of METTL3 inhibitor STM2457 alone and combined with the chemotherapeutic drug cisplatin on cervical cancer. Through the above methods, new treatment strategies are used to solve the drug resistance of cervical cancer patients, so as to achieve the best effect of treating cervical cancer.

The invention provides application of pentafluridol and a pharmaceutical composition thereof in preparation of antitumor drugs. According to the invention, it is found for the first time that penfluridol induces copper death through a PDPK1-AKT1-CTR1 signal axis, and innovative application of existing drugs in the prior art is realized. The invention discloses a new anti-cancer mechanism, and provides a new target for tumor treatment; through preparation of the novel pharmaceutical composition, combined chemotherapy sensitization is realized. The pentafluridol is used as a traditional antipsychotic drug, the drug safety is comprehensively verified, the transformation potential is high, drug redevelopment can be rapidly promoted, and the pentafluridol has clinical application value.

This invention relates to a combination chemotherapy drug for solid tumors, comprising any clinically used chemotherapy drug combined with a mitochondrial extract to form the active pharmaceutical ingredient, wherein the mitochondrial extract and the clinically used chemotherapy drug are each an independent drug delivery unit. Experiments of this invention have demonstrated that the combined use of the mitochondrial extract and the chemotherapy drug effectively enhances the drug's efficacy compared to using the chemotherapy drug alone, thereby improving the therapeutic effect of chemotherapy for solid tumors.

The invention discloses plasma extracellular vesicles miR-140-5p, miR-597-3p and miR-92a-1-5p which can be used as biomarkers for monitoring or prognosing the curative effect of immune combined chemotherapy of lung cancer, so that the plasma extracellular vesicles miR-140-5p, miR-597-3p and miR-92a-1-5p can be used for preparing a chip, a detection reagent or a detection kit for monitoring or prognosing the curative effect of immune combined chemotherapy of lung cancer. The plasma extracellular vesicle miRNA biomarker disclosed by the invention can be used for accurately screening potential people who benefit from lung cancer immune combined chemotherapy, and particularly accurately subdividing and monitoring the curative effect of the people who benefit from lung cancer immune combined chemotherapy.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The invention belongs to the technical field of biological medicine, and particularly relates to a wide-period small cell lung cancer immune combined chemotherapy prognostic marker combination and application thereof. The biomarker combination is easy and convenient to sample, biopsy tissue does not need to be provided, and only peripheral blood needs to be taken for detection. The biomarker combination is high in accuracy, training is concentrated, the area under an AUC curve of a combined prediction model is 0.803, the optimal Cut-off value is 0.51, the sensitivity is 83.7%, and the specificity is 76.5%. The combined index prediction efficiency is good, and a single index cannot be predicted. In a constructed prediction model by applying independent external verification, the joint prediction AUC is 0.789, and when 0.51 is a Cut-off value, the sensitivity of the model is 82.1%, and the specificity is 63.6%. The combined index prediction efficiency is good, and a single index cannot be predicted. The method has practicability, and provides precise treatment guidance for clinical medicine.

The application belongs to the field of biological detection and relates to a kind of establishment and clinical use for bladder cancer prognosis risk marker.The marker is composed of 23 mutant genes of AHNAK2,RYR2,USH2A,DCHS2,BRCA2,RP1L1,FBN2,ZFYVE26,ANK1,NCOR1,F8,WNK1,IGSF10,COL11A1,RANBP2,MED1,FANCM,MYO18B,ZNFX1,MROH2B,AUTS2,CNOT1,COL5A1.The application screens reliable and independent biomarker which can effectively predict the clinical prognosis of bladder patients.Provides a best mutant marker as potential prognostic biomarker and prediction model for combined chemotherapy response of bladder patients.

The application discloses application of exosome miRNA markers in evaluation of curative effect of immunotherapy combined with chemotherapy on small cell lung cancer patients. The exosome miRNA markers are a combination of miR-338-5p, miR-345-5p, miR-150-5p, miR-7706 and miR-328-3p. It is found for the first time that a combination of plasma exosome miRNA and TNM stage can be used as a marker to effectively predict a population benefiting from an immunotherapy combined with chemotherapy treatment scheme. Due to the unique structure of the exosome and the advantages of liquid biopsy technology, the exosome miR-338-5p, miR-345-5p, miR-150-5p, miR-7706, miR-328-3p and TNM stage combination of the application has high sensitivity and convenience as a population screening for benefiting from an immunotherapy combined with chemotherapy combined treatment scheme.

The present application relates to the technical field of disease risk prediction, in particular to a risk prediction method for adverse reactions and complications of resectable NSCLC neoadjuvant immunotherapy during the perioperative period based on nomogram and application. The method comprises the following steps: screening relevant variables by single factor Logistic regression; introducing the screened variables into multi-factor Logistic regression to determine independent prediction factors, and constructing a prediction model and a nomogram according to the independent prediction factors; and evaluating the model discrimination degree by using a ROC curve, and evaluating the model calibration ability by using a Hosmer-Lemeshow test and a calibration ROC curve. The neoadjuvant immunotherapy combined with chemotherapy has a significant treatment effect (MPR rate 51.43%, PCR rate 31.43%), the incidence of treatment-related adverse reactions is 58.57%, and the incidence of postoperative complications is 44.28%. Through multi-factor analysis, it is determined that erythrocyte sedimentation rate (> 20 mm / h), intraoperative blood loss (> 200 ml) and postoperative hospitalization time (> 1 week) are independent risk factors for perioperative complications, and the risk prediction model constructed according to the independent risk factors has good prediction performance.

The application belongs to the field of biological medicine, and relates to a combination of a DR5 agonist and an immune checkpoint inhibitor for preparing a drug for treating tumors. The application provides application of a death receptor 5 agonist in preparation of an anti-tumor drug in combination with one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a NKG2A inhibitor and a chemotherapeutic drug. It is found that the DR5 agonistic antibody can further increase the single drug efficacy of the immune checkpoint inhibitor. On this basis, the DR5 agonistic antibody and the immune checkpoint inhibitor can also be combined with chemotherapy to further improve the effect of immunotherapy. The application can further promote the development of immunotherapy in the field of tumor treatment, optimize the tumor treatment pattern, and is expected to be applied in the clinic to improve the tumor treatment effect and the survival rate of patients.